Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again." ...

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s ...

Passive income can help secure your retirement, but building a dependable income is not easy. You must be able to identify stocks to buy and hold for decades. There are top-tier dividend stocks with ...